People: Zogenix Inc (ZGNX.O)

ZGNX.O on Consolidated Issue listed on NASDAQ Global Market

1.75USD
11 Jul 2014
Price Change (% chg)

$-0.01 (-0.57%)
Prev Close
$1.76
Open
$1.78
Day's High
$1.82
Day's Low
$1.74
Volume
894,252
Avg. Vol
2,753,230
52-wk High
$5.19
52-wk Low
$1.50

Search Stocks

Farr, Stephen 

Brief Biography

Dr. Stephen J. Farr, Ph.D., is President, Director of Zogenix, Inc. He is one of our co-founders and has served as our President and as a member of our board of directors since our inception in May 2006. From May 2006 to August 2006, Dr. Farr also served as our Chief Executive Officer and from August 2006 to March 2013, Dr. Farr also served as our Chief Operating Officer. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales. As one of our co-founders and having served as our President since May 2006, Dr. Farr’s extensive knowledge of our business, history and culture, including his in-depth involvement with the DosePro technology and the development of Sumavel DosePro and Zohydro ER, as well as his significant experience in research and development and thorough knowledge of the pharmaceutical product development process, contributed to our board of directors’ conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
530,174 -- 797,591 1,402,760

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Cam Garner

--

Stephen Farr

1,402,760

Roger Hawley

1,834,500

Ann Rhoads

958,047

Bradley Galer

989,422

R. Scott Shively

989,635
As Of 30 Dec 2013
Search Stocks